TGTXTG Therapeutics, Inc.

$5B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38,000-0.3% YoY

Gross Profit

$38,000100.0% margin

Operating Income

-$34M-90336.8% margin

Net Income

-$34M-89344.7% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

-$173,000

Balance Sheet

Total Assets

$114M

Total Liabilities

$43M

Stockholders' Equity

$72M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38,000	$38,096	-0.3%
Gross Profit	$38,000	$38,096	-0.3%
Operating Income	-$34M	-$32M	-8.7%
Net Income	-$34M	-$32M	-7.7%

TGTX Q3 2018 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena